FIELD: medicine.
SUBSTANCE: group of inventions refers to cancer treatment. Disclosed are: a therapeutic composition for inhibiting histone methyltransferase EZH2, containing N-(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-diphenyl]-3-carboxamide or a salt thereof and one or more other therapeutic agents, selected from anticancer agents or glucocorticoids (preferably dexamethasone or prednisone); method of treatment using it; method of treating cancer; method of inhibiting cancer cell proliferation (versions).
EFFECT: technical result consists in synergetic action on reducing the viability of cancer cells and tumor growth inhibition.
34 cl, 10 dwg, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| HUMAN EZH2 INHIBITORS AND METHODS FOR USE THEREOF | 2013 |
|
RU2704445C2 |
| HUMAN EZH2 INHIBITORS AND METHODS OF APPLICATION THEREOF | 2011 |
|
RU2618475C2 |
| HUMAN EZH2 INHIBITORS AND METHODS FOR APPLICATION THEREOF | 2011 |
|
RU2765155C2 |
| METHODS OF TREATING CANCER | 2013 |
|
RU2677276C2 |
| AXL SIGNALLING INHIBITION IN ANTIMETASTATIC THERAPY | 2011 |
|
RU2556822C2 |
| COMBINED THERAPY FOR CANCER TREATMENT | 2016 |
|
RU2731202C2 |
| MODULATORS OF HEPATOCYTE GROWTH FACTOR ACTIVATOR | 2005 |
|
RU2418004C2 |
| USE OF CD 151 ANTIBODIES FOR TREATING CANCER | 2007 |
|
RU2464041C2 |
| TREATING PATIENTS DIAGNOSED WITH PANCREATIC DUCT ADENOCARCINOMA WITH USING EPIDERMAL GROWTH FACTOR (EGFR) RECEPTOR MONOCLONAL ANTIBODIES | 2016 |
|
RU2728571C2 |
| POLYPEPTIDE WITH ANTIVIRAL, ANTIPROLIFERATIVE AND/OR IMMUNOMODULATING ACTIVITIES, SEPARATED POLYNUCLEOTIDE | 2002 |
|
RU2328528C2 |
